Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Organon (OGN) is receiving significant investor attention. The pharmaceutical company shows declining earnings estimates for the current fiscal year (-7.9%) but modest growth expected for next year (+7%). Revenue growth remains flat to slightly negative. With a Zacks Rank #3 (Hold) rating and a Grade A valuation score indicating the stock trades at a discount to peers, the company is expected to perform in line with the broader market in the near term.